CXCL10

Summary

CXCL10 (C-X-C motif chemokine ligand 10, HGNC:10637) is a protein-coding gene on chromosome 4q21.1, encoding C-X-C motif chemokine 10 (P02778). Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects.

This antimicrobial gene encodes a chemokine of the CXC subfamily and ligand for the receptor CXCR3. Binding of this protein to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression. This gene may also be a key regulator of the ‘cytokine storm’ immune response to SARS-CoV-2 infection.

Source: NCBI Gene 3627 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complement component 7 deficiency (Strong, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 698 total — 41 pathogenic, 20 likely-pathogenic
• Phenotypes (HPO): 4
• Druggable target: yes
• MANE Select transcript: NM_001565

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10637
Approved symbol	CXCL10
Name	C-X-C motif chemokine ligand 10
Location	4q21.1
Locus type	gene with protein product
Status	Approved
Aliases	IFI10, IP-10, crg-2, mob-1, C7, gIP-10
Ensembl gene	ENSG00000169245
Ensembl biotype	protein_coding
OMIM	147310
Entrez	3627

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000306602

RefSeq mRNA: 1 — MANE Select: NM_001565 NM_001565

CCDS: CCDS43240

Canonical transcript exons

ENST00000306602 — 4 exons

Exon	Start	End
ENSE00001126423	76023371	76023497
ENSE00001139442	76022366	76022455
ENSE00001139451	76022691	76022817
ENSE00001193218	76021118	76021948

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 92.40.

FANTOM5 (CAGE): breadth broad, TPM avg 161.3239 / max 27614.2309, expressed in 506 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52632	161.2414	506
52631	0.0825	38

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vermiform appendix	UBERON:0001154	92.40	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.00	gold quality
decidua	UBERON:0002450	87.48	gold quality
lymph node	UBERON:0000029	86.75	gold quality
rectum	UBERON:0001052	84.48	gold quality
caecum	UBERON:0001153	84.38	gold quality
monocyte	CL:0000576	84.11	gold quality
mononuclear cell	CL:0000842	83.94	gold quality
leukocyte	CL:0000738	83.75	gold quality
granulocyte	CL:0000094	83.56	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.70	gold quality
smooth muscle tissue	UBERON:0001135	82.65	gold quality
epithelium of nasopharynx	UBERON:0001951	82.32	gold quality
nasopharynx	UBERON:0001728	82.31	gold quality
palpebral conjunctiva	UBERON:0001812	80.89	gold quality
germinal epithelium of ovary	UBERON:0001304	80.81	gold quality
pancreatic ductal cell	CL:0002079	79.10	silver quality
gall bladder	UBERON:0002110	79.08	gold quality
nasal cavity epithelium	UBERON:0005384	76.61	gold quality
cervix squamous epithelium	UBERON:0006922	76.59	gold quality
periodontal ligament	UBERON:0008266	76.25	gold quality
nasal cavity mucosa	UBERON:0001826	75.22	gold quality
superficial temporal artery	UBERON:0001614	75.14	gold quality
spleen	UBERON:0002106	74.24	gold quality
pericardium	UBERON:0002407	73.78	gold quality
type B pancreatic cell	CL:0000169	73.53	gold quality
olfactory bulb	UBERON:0002264	73.49	gold quality
mucosa of urinary bladder	UBERON:0001259	73.00	gold quality
parotid gland	UBERON:0001831	72.81	gold quality
upper lobe of left lung	UBERON:0008952	72.80	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-8	yes	4992.54
E-CURD-114	yes	3876.86
E-HCAD-1	yes	3361.80
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): DDIT3, GLI2, HAND1, IL16, IRF1, IRF2, IRF3, IRF5, IRF6, IRF7, IRF9, IRX2, JUN, KLF4, NCOR1, NFKB1, NFKB, NFKBIA, NFKBID, PARP1, PTPN22, REL, RELA, STAT1, STAT3, TSC22D3

miRNA regulators (miRDB)

64 targeting CXCL10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-6505-5P	99.73	69.25	1595
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-3942-3P	99.57	69.03	2854

Literature-anchored findings (GeneRIF, showing 40)

• In a mouse model, this protein is expressed as a marker of hepatic inflammation and injury, suggesting a role in liver repair and regeneration. (PMID:11418676)
• Production by endometrial stromal cells is regulated by inflammatory mediators; Level may regulate leukocyte trafficking in the endometrium (PMID:11818520)
• synthesis was detected in human Leydig cells exposed to the Sendai virus, but not in human total germ cells (PMID:11897701)
• These findings suggest that the CXCR3/CXCL10 axis may be involved in the T cell recruitment that occurs in peripheral airways of smokers with COPD and that these T cells may have a type-1 profile. (PMID:12016104)
• bacterium-induced CXCL10(IP-10) secretion by osteoblast can be mediated in part through toll-like receptor 4 (PMID:12117914)
• Leishmania promastigotes release a granulocyte chemotactic factor and inhibit gamma-interferon-inducible protein 10 production by neutrophil granulocyte (PMID:12117926)
• The IFN-gamma-inducible IP-10 protein was induced in human brain microvascular endothelial cells and astrocytes only after inflammatory stimuli. (PMID:12162873)
• The structure of IP-10 has been solved by NMR spectroscopy and the surface of IP-10 that interacts with the N-terminus of the receptor CXCR3 has been defined. (PMID:12173928)
• circulating IP-10 concentrations is increased in patients with Type I diabetes, but only during the early and subclinical stage of the disease. (PMID:12189440)
• Gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil. (PMID:12270371)
• Increased levels of CXCL10 in cerebrospinal fluid were found in a subgroup of MS patients. (PMID:12356205)
• IFNgamma stimulates the production of IP-10 and Mig in the SS ductal epithelium, and that IP-10 and Mig are involved in the accumulation of T cell infiltrates in the SS salivary gland. (PMID:12384933)
• complex gene expression regulation for IP-10 in peripheral blood t lymphocytes, involving both calcineurin-dependent and -independent pathways, is demonstrated (PMID:12393716)
• release is evoked by tumor necrosis factor-alpha and interferon-gamma in HaCaT cell line by interleukin-4 (PMID:12441140)
• highly expressed by mumps virus-infected Leydig cells and ribavirin does not block IP-10 production (PMID:12584353)
• 17beta-estradiol inhibited interferon-gamma-induced interferon-induced protein of 10 kDa secretion, mRNA expression, and promoter activity in keratinocytes; effects may be mediated by cell surface receptors (PMID:12603854)
• infection with cytomegalovirus was found to elicit the production of CXCL10 from primary microglial cells but not from astrocytes; CXCL10 production was regulated by human and viral interleukin-10 (PMID:12663757)
• This chemokine receptor stimulates HIV-1 replication. (PMID:12667820)
• IP-10 expression and secretion in human monocytic cells is selectively induced by leptin (PMID:12668159)
• Regulation of interferon-inducible cytokine IP-10 expression in rheumatoid arthritis. (PMID:12718750)
• expression in serum and liver highest in chronic hepatitis C and correlates with accumulation of Il-18 and INFgamma mRNA in chronic hepatitis C, but not in hepatitis B nor in nonviral liver disorders (PMID:12794718)
• Data suggest that in oral lichen planus, the presence of CCL5 and CXCL10 in the cytolytic granules of tissue-infiltrating CD8(+)T cells expressing CCR5 and CXCR3 reveals a potential self-recruiting mechanism involving activated effector cytotoxic T cells (PMID:12819030)
• Cannot be related to islet autoimmune processes in IDDM. (PMID:12819903)
• A higher amount of IP-10 mRNA is expressed after exposure of keratinocytes to interferon-gamma, leading to migration of T cells from the dermis to the epidermis and representing a second step of chemotaxis following T cell recruitment from blood. (PMID:12847282)
• CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. (PMID:12884299)
• Constitutive NF-kappaB activity is required for the induced gene expression of CXCL10 in tumour cell lines in response to IFNgamma. (PMID:12946268)
• CXCL10 displays antimicrobial activity against E. coli and S. aureus. (PMID:12949249)
• Peak of expression of CXCL9 and CXCL10 occurred 4 days before CD8+ T cells infiltrated infected tissues. CXCL9 and CXCL10 may play role early during immune response against rickettsial infections. (PMID:14507644)
• MIG and IP-10 are cleaved by gelatinase B and neutrophil collagenase (PMID:14550288)
• In restinosis, increased plasma concentrations of IP10 were accompanied by a compensatory decrease in the CXCR3 expression on lymphocytes, but not monocytes, suggesting that a high plasma concentration of IP10 strongly induces monocytes signaling. (PMID:14578618)
• both at molecular and protein levels CXCL10 and CXCL12 significantly increased only when cells were differentiated on calcium phosphate-coated slides (PMID:14600836)
• furin is a novel chemokine-modifying enzyme in vitro and most probably also in vivo, generating a C-terminally truncated CXCL10, which fully retains its (inverse) agonistic properties. (PMID:14739277)
• Nitric oxide suppressed IP-10 expression. (PMID:15063730)
• Chronic production of CXCL10 does not alter synaptic plasticity in CXCL10 transgenic (TG)mouse hippocampal slices. By contrast, exogenous recombinant CXCL10 significantly inhibits long-term potentiation in slices from normal C57Bl/6J and CXCL10 TG mice. (PMID:15081247)
• The chemokine CXCL10, usually associated with Th1 cells, is elevated in serum of patients with acute Syndenham’s chorea. (PMID:15081261)
• CXCL9, CXCL10, and CXCL11 functions are mediated by intracellular domains of CXCR3 (PMID:15150261)
• Pretransplant serum CXCL10 levels might represent a clinically useful parameter to identify subjects who are at high risk of severe rejection and graft failure. (PMID:15307834)
• TRAIL pretreatment of endothelial cells down-modulated mRNA steady-state levels of several TNF-alpha-induced chemokines, and it abrogated the TNF-alpha-mediated up-regulation of CCL8 and CXCL10, modulating leukocyte/endothelial cell adhesion (PMID:15644410)
• These data indicate that IFN-gamma mediates the recruitment of lymphocytes into the lung via production of the chemokine CXCL10, resulting in Tc1-cell alveolitis and granuloma formation. (PMID:15725351)
• increased CXCL10 especially in hypothyroid patients with a more aggressive disorder, and normal CCL2 serum levels in autoimmune thyroiditis (PMID:15745922)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cxcl10	ENSMUSG00000034855
rattus_norvegicus	Cxcl10	ENSRNOG00000022256

Paralogs (12): CXCL2 (ENSG00000081041), PF4V1 (ENSG00000109272), CXCL6 (ENSG00000124875), CXCL9 (ENSG00000138755), CXCL13 (ENSG00000156234), CXCL3 (ENSG00000163734), CXCL5 (ENSG00000163735), PPBP (ENSG00000163736), PF4 (ENSG00000163737), CXCL1 (ENSG00000163739), CXCL11 (ENSG00000169248), CXCL8 (ENSG00000169429)

Protein

Protein identifiers

C-X-C motif chemokine 10 — P02778 (reviewed: P02778)

Alternative names: 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10

All UniProt accessions (1): P02778

UniProt curated annotations — full annotation on UniProt →

Function. Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects. Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites. Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization. In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation. Activation of the CXCL10/CXCR3 axis also plays an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization.

Subunit / interactions. Monomer, dimer, and tetramer. Interacts with CXCR3 (via N-terminus).

Subcellular location. Secreted.

Tissue specificity. Mainly secreted by monocytes, endothelial cells as well as fibroblasts. Expressed by epithelial cells in thymus. Microglial cells produce CXCL10 in response to viral stimulation.

Post-translational modifications. Several proteases can mediate post-secretion cleavages. DPP4 cleaves CXCL10 on its N-terminal 2 amino acids leading to an antagonist form of CXCL10. This dominant negative form is capable of binding CXCR3 but does not induce signaling. MMP9 cleaves 9 amino acids instead.

Induction. By IFNG/IFN-gamma. A diverse population of cell types rapidly increases transcription of mRNA encoding this protein. This suggests that gamma-induced protein may be a key mediator of the IFNG/IFN-gamma response.

Similarity. Belongs to the intercrine alpha (chemokine CxC) family.

RefSeq proteins (1): NP_001556* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001089	Chemokine_CXC	Family
IPR001811	Chemokine_IL8-like_dom	Domain
IPR018048	Chemokine_CXC_CS	Conserved_site
IPR033899	CXC_Chemokine_domain	Domain
IPR036048	Interleukin_8-like_sf	Homologous_superfamily
IPR039809	Chemokine_b/g/d	Family

Pfam: PF00048

UniProt features (15 total): strand 5, chain 2, turn 2, disulfide bond 2, signal peptide 1, helix 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
1O7Z	X-RAY DIFFRACTION	1.92
1O80	X-RAY DIFFRACTION	2
1O7Y	X-RAY DIFFRACTION	3
9P0L	ELECTRON MICROSCOPY	3.1
8K2X	ELECTRON MICROSCOPY	3.2
1LV9	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P02778-F1	89.67	0.71

Antibody-complex structures (SAbDab): 1 — 8K2X

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 26

Disulfide bonds (2): 30–57, 32–74

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-380108	Chemokine receptors bind chemokines
R-HSA-418594	G alpha (i) signalling events
R-HSA-6783783	Interleukin-10 signaling

MSigDB gene sets: 815 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_POSITIVE_REGULATION_OF_CALCIUM_ION_TRANSPORT, CREL_01, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, MODULE_92, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_VIRUS, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, GOBP_REGULATION_OF_T_CELL_CHEMOTAXIS, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CIRCULATORY_SYSTEM_PROCESS

GO Biological Process (41): chemotaxis (GO:0006935), inflammatory response (GO:0006954), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), cell-cell signaling (GO:0007267), muscle organ development (GO:0007517), blood circulation (GO:0008015), positive regulation of cell population proliferation (GO:0008284), response to gamma radiation (GO:0010332), T cell chemotaxis (GO:0010818), regulation of T cell chemotaxis (GO:0010819), response to auditory stimulus (GO:0010996), negative regulation of angiogenesis (GO:0016525), neutrophil chemotaxis (GO:0030593), response to vitamin D (GO:0033280), cellular response to heat (GO:0034605), endothelial cell activation (GO:0042118), regulation of cell population proliferation (GO:0042127), regulation of apoptotic process (GO:0042981), negative regulation of myoblast differentiation (GO:0045662), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of release of sequestered calcium ion into cytosol (GO:0051281), chemokine-mediated signaling pathway (GO:0070098), cellular response to lipopolysaccharide (GO:0071222), positive regulation of monocyte chemotaxis (GO:0090026), cellular response to interleukin-17 (GO:0097398), cellular response to virus (GO:0098586), antiviral innate immune response (GO:0140374), regulation of endothelial tube morphogenesis (GO:1901509), negative regulation of myoblast fusion (GO:1901740), positive regulation of T cell migration (GO:2000406), positive regulation of leukocyte chemotaxis (GO:0002690), defense response (GO:0006952), immune response (GO:0006955), response to bacterium (GO:0009617), positive regulation of cell migration (GO:0030335), response to lipopolysaccharide (GO:0032496), positive chemotaxis (GO:0050918)

GO Molecular Function (9): signaling receptor binding (GO:0005102), chemokine activity (GO:0008009), heparin binding (GO:0008201), cAMP-dependent protein kinase regulator activity (GO:0008603), chemoattractant activity (GO:0042056), CXCR chemokine receptor binding (GO:0045236), CXCR3 chemokine receptor binding (GO:0048248), cytokine activity (GO:0005125), protein binding (GO:0005515)

GO Cellular Component (3): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), external side of plasma membrane (GO:0009897)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Peptide ligand-binding receptors	1
GPCR downstream signalling	1
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	2
signaling	2
regulation of cellular process	2
signal transduction	2
cell population proliferation	2
chemokine receptor binding	2
receptor ligand activity	2
response to chemical	1
taxis	1
defense response	1
cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase activator activity	1
animal organ development	1
muscle structure development	1
circulatory system process	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
response to ionizing radiation	1
lymphocyte chemotaxis	1
T cell migration	1
T cell chemotaxis	1
regulation of lymphocyte chemotaxis	1
regulation of T cell migration	1
response to mechanical stimulus	1
angiogenesis	1
regulation of angiogenesis	1
negative regulation of blood vessel morphogenesis	1
granulocyte chemotaxis	1
neutrophil migration	1
response to vitamin	1
response to lipid	1
response to oxygen-containing compound	1
response to heat	1
cellular response to stress	1
cell activation	1
protein binding	1
cytokine activity	1

Protein interactions and networks

STRING

3742 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CXCL10	CXCR3	P49682	999
CXCL10	CCR5	P51681	997
CXCL10	CCR2	P41597	996
CXCL10	CXCR4	P30991	992
CXCL10	CCR1	P32246	984
CXCL10	CXCL1	P09341	984
CXCL10	CXCR2	P25025	978
CXCL10	CCR3	P51677	975
CXCL10	CXCR1	P25024	970
CXCL10	TLR4	O00206	968
CXCL10	CCL5	P13501	951
CXCL10	CXCL8	P10145	948
CXCL10	CXCL5	P42830	947
CXCL10	IFNG	P01579	942
CXCL10	CXCL13	O43927	940

IntAct

30 interactions, top by confidence:

A	B	Type	Score
DPP4	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.620
DPP4	CXCL10	psi-mi:“MI:0194”(cleavage reaction)	0.620
CXCL10	CCL5	psi-mi:“MI:0407”(direct interaction)	0.560
CXCL10	PF4	psi-mi:“MI:0407”(direct interaction)	0.560
CXCL10	CXCL12	psi-mi:“MI:0407”(direct interaction)	0.560
PF4	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.560
CXCL10	CCL8	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CCL11	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CCL13	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CCL21	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CCL26	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CCL28	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CXCL6	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CXCL9	psi-mi:“MI:0407”(direct interaction)	0.440
CCL11	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CCL13	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CCL21	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CCL26	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CCL28	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
XCL1	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
PF4V1	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
PPBP	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL9	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL14	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CXCL11	psi-mi:“MI:0407”(direct interaction)	0.440
CXCL10	CXCL17	psi-mi:“MI:0407”(direct interaction)	0.440
DPP8	CXCL10	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (26): CXCL10 (Reconstituted Complex), CXCL10 (Reconstituted Complex), CXCL10 (Synthetic Lethality), CXCL10 (Reconstituted Complex), CXCL10 (Reconstituted Complex), CXCL10 (Reconstituted Complex), CXCL10 (Reconstituted Complex), CXCL10 (Reconstituted Complex), CCL11 (Reconstituted Complex), CCL13 (Reconstituted Complex), CCL21 (Reconstituted Complex), CCL26 (Reconstituted Complex), CCL28 (Reconstituted Complex), CCL5 (Reconstituted Complex), CCL8 (Reconstituted Complex)

ESM2 similar proteins: A0A0R4INB9, A9QWP9, B0R191, K7XWG4, O43927, O55038, O62812, P02776, P02778, P06765, P10145, P10146, P10720, P17515, P18340, P19874, P22362, P26894, P36925, P41324, P43030, P46653, P48298, P48973, P49113, P67813, P67814, P78556, P79255, P80325, P82943, P97545, P97884, P97885, Q03366, Q07325, Q09141, Q102R3, Q2KIQ8, Q5KSV9

Diamond homologs: A0A0R4INB9, A9QWP9, A9QWQ1, B0R191, O14625, O46678, P02775, P02778, P08317, P09341, P12850, P17515, P19875, P19876, P22952, P42830, P48973, P50228, P80162, P80221, P82535, P97885, Q07325, Q2KIQ8, Q5KSV9, Q865F5, Q8MIZ1, Q9JHH5, O46675, O46676, O46677, O55235, O62812, P02776, P06765, P09340, P10145, P10720, P10889, P14095

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CXCL10	“up-regulates activity”	CXCR3	binding
CXCL10	up-regulates	Immune_response
CXCL10	up-regulates	ARDS
IRX2	“down-regulates quantity by repression”	CXCL10	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 19 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chemokine receptors bind chemokines	12	160.5×	5e-25
Class A/1 (Rhodopsin-like receptors)	6	31.8×	1e-07
Peptide ligand-binding receptors	6	31.8×	1e-07
G alpha (i) signalling events	10	27.8×	2e-12
GPCR ligand binding	6	27.5×	2e-07
Signaling by GPCR	6	17.2×	3e-06
GPCR downstream signalling	5	15.5×	5e-05

GO biological processes:

GO term	Partners	Fold	FDR
eosinophil chemotaxis	6	231.4×	3e-12
chemokine-mediated signaling pathway	12	204.7×	2e-24
neutrophil chemotaxis	8	120.3×	4e-14
antimicrobial humoral immune response mediated by antimicrobial peptide	13	110.9×	2e-23
chemotaxis	11	78.7×	1e-17
cell chemotaxis	6	58.5×	1e-08
intracellular calcium ion homeostasis	5	38.2×	2e-06
response to virus	5	37.9×	2e-06

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

698 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	41
Likely pathogenic	20
Uncertain significance	303
Likely benign	260
Benign	25

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
12103	NM_000587.4(C7):c.2184T>A (p.Cys728Ter)	Pathogenic
12104	NM_000587.4(C7):c.2140_2141del (p.Val714fs)	Pathogenic
12106	NM_000587.4(C7):c.63-1G>A	Pathogenic
12107	C7, EX7-8DEL	Pathogenic
12109	NM_000587.4(C7):c.1314del (p.Lys438fs)	Pathogenic
12111	NM_000587.4(C7):c.1458T>A (p.Cys486Ter)	Pathogenic
12112	C7, 11-BP DEL, NT631	Pathogenic
1399210	NM_000587.4(C7):c.1063G>T (p.Glu355Ter)	Pathogenic
1430910	NM_000587.4(C7):c.1518G>A (p.Trp506Ter)	Pathogenic
1437215	NM_000587.4(C7):c.2166-1_2166insGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCGGATCACGAGGTCAGGAGATCGAGACCATACTGNNNNNNNNNNAAAAAAAAAAAAAAAAAAAAAAAAATTCTTTTCAG	Pathogenic
1452580	NM_000587.4(C7):c.2202del (p.Ser734fs)	Pathogenic
1453343	NM_000587.4(C7):c.93del (p.Phe32fs)	Pathogenic
1455140	NC_000005.9:g.(?40947684)(40950136_?)del	Pathogenic
1460411	NM_000587.4(C7):c.468del (p.Asn157fs)	Pathogenic
1901592	NM_000587.4(C7):c.2188C>T (p.Gln730Ter)	Pathogenic
1953572	NM_000587.4(C7):c.877C>T (p.Arg293Ter)	Pathogenic
2050643	NM_000587.4(C7):c.811C>T (p.Gln271Ter)	Pathogenic
2053213	NM_000587.4(C7):c.781C>T (p.Gln261Ter)	Pathogenic
2123406	NM_000587.4(C7):c.721G>T (p.Glu241Ter)	Pathogenic
2188741	NM_000587.4(C7):c.952del (p.Tyr318fs)	Pathogenic
2717734	NM_000587.4(C7):c.38dup (p.Gly14fs)	Pathogenic
2770748	NM_000587.4(C7):c.881_882del (p.Arg294fs)	Pathogenic
280140	NM_000587.4(C7):c.1924_1925del (p.His643fs)	Pathogenic
2801945	NM_000587.4(C7):c.2092_2095del (p.Ala698fs)	Pathogenic
2990929	NM_000587.4(C7):c.448C>T (p.Gln150Ter)	Pathogenic
3001628	NM_000587.4(C7):c.936del (p.Glu312fs)	Pathogenic
3246448	NC_000005.9:g.(?40958115)(40959742_?)del	Pathogenic
3619308	NM_000587.4(C7):c.1088del (p.Ala363fs)	Pathogenic
3646284	NM_000587.4(C7):c.856_857del (p.Leu286fs)	Pathogenic
3656263	NM_000587.4(C7):c.398del (p.Pro133fs)	Pathogenic

SpliceAI

5393 predictions. Top by Δscore:

Variant	Effect	Δscore
4:76022361:CCTA:C	donor_loss	1.0000
4:76022365:C:CG	donor_loss	1.0000
4:76022369:T:A	donor_gain	1.0000
4:76022451:TAGCA:T	acceptor_gain	1.0000
4:76022452:AGCA:A	acceptor_gain	1.0000
4:76022453:GCA:G	acceptor_gain	1.0000
4:76022453:GCAC:G	acceptor_loss	1.0000
4:76022454:CA:C	acceptor_gain	1.0000
4:76022454:CAC:C	acceptor_gain	1.0000
4:76022456:C:CC	acceptor_gain	1.0000
4:76022456:C:CG	acceptor_loss	1.0000
4:76022457:T:C	acceptor_loss	1.0000
4:76022458:G:C	acceptor_gain	1.0000
4:76022458:G:GC	acceptor_gain	1.0000
4:76022464:A:AC	acceptor_gain	1.0000
4:76022464:A:C	acceptor_gain	1.0000
4:76022685:ACTC:A	donor_loss	1.0000
4:76022687:TCA:T	donor_loss	1.0000
4:76022688:CA:C	donor_loss	1.0000
4:76022689:A:AC	donor_gain	1.0000
4:76022689:ACA:A	donor_loss	1.0000
4:76022690:C:CC	donor_gain	1.0000
4:76022813:TACTC:T	acceptor_gain	1.0000
4:76022815:CTC:C	acceptor_gain	1.0000
4:76022816:TC:T	acceptor_gain	1.0000
4:76022816:TCCTG:T	acceptor_loss	1.0000
4:76022817:CC:C	acceptor_gain	1.0000
4:76022817:CCTGT:C	acceptor_loss	1.0000
4:76022818:C:CA	acceptor_loss	1.0000
4:76022818:C:CC	acceptor_gain	1.0000

AlphaMissense

639 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:76022423:C:G	C74S	0.969
4:76022424:A:T	C74S	0.969
4:76022453:G:T	A64D	0.962
4:76022424:A:G	C74R	0.960
4:76022710:A:G	C57R	0.954
4:76022709:C:G	C57S	0.951
4:76022710:A:T	C57S	0.951
4:76022790:C:G	C30S	0.951
4:76022791:A:T	C30S	0.951
4:76022784:C:G	C32S	0.940
4:76022785:A:T	C32S	0.940
4:76022694:A:G	I62T	0.938
4:76022708:A:C	C57W	0.938
4:76022694:A:C	I62S	0.937
4:76022422:A:C	C74W	0.933
4:76022709:C:T	C57Y	0.933
4:76022791:A:G	C30R	0.930
4:76022736:A:T	L48H	0.928
4:76022785:A:G	C32R	0.918
4:76022696:C:A	E61D	0.915
4:76022696:C:G	E61D	0.915
4:76022710:A:C	C57G	0.910
4:76022454:C:G	A64P	0.907
4:76022783:G:C	C32W	0.906
4:76022420:A:G	L75P	0.904
4:76022736:A:G	L48P	0.903
4:76022784:C:T	C32Y	0.902
4:76022697:T:C	E61G	0.899
4:76022789:A:C	C30W	0.897
4:76022709:C:A	C57F	0.893

dbSNP variants (sampled 300 via entrez): RS1000929937 (4:76023629 A>C), RS10014837 (4:76020665 G>A,C,T), RS1002751668 (4:76021479 C>A), RS1003151410 (4:76021171 T>C), RS1003678109 (4:76024771 G>A), RS1005072012 (4:76021700 A>G), RS1005123037 (4:76021279 T>C), RS1005322189 (4:76020800 G>A,C), RS1006029121 (4:76023505 G>A,T), RS1006125710 (4:76023067 A>G), RS1006132914 (4:76024403 A>C), RS1006473713 (4:76024177 A>G), RS1006944089 (4:76024783 G>A), RS1007047175 (4:76025196 A>T), RS1007989016 (4:76023990 C>G)

Disease associations

OMIM: gene MIM:147310 | disease phenotypes: MIM:610102

GenCC curated gene-disease

Disease	Classification	Inheritance
complement component 7 deficiency	Strong	Autosomal recessive

Mondo (1): complement component 7 deficiency (MONDO:0012412)

Orphanet (0):

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0005381	Recurrent meningococcal disease
HP:0005430	Recurrent Neisserial infections
HP:0033058	Decreased circulating complement C7 concentration

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST002777_10	Clozapine-induced cytotoxicity	9.000000e-06
GCST003265_284	Post bronchodilator FEV1/FVC ratio in COPD	5.000000e-06
GCST004440_23	Interferon gamma-induced protein 10 levels	3.000000e-15
GCST006585_2581	Blood protein levels	5.000000e-08
GCST006622_14	Neonatal cytokine/chemokine levels (fetal genetic effect)	2.000000e-14
GCST007009_3	Hippocampal volume	7.000000e-07
GCST007009_4	Hippocampal volume	3.000000e-07
GCST008199_1	Interferon gamma-induced protein 10 levels	3.000000e-13
GCST009562_1	C-X-C motif chemokine 10 levels	7.000000e-37

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0006952	cytotoxicity measurement
EFO:0004713	FEV/FVC ratio
EFO:0008056	C-X-C motif chemokine 10 measurement
EFO:0004747	protein measurement
EFO:0007959	fetal genotype effect measurement
EFO:0008057	C-X-C motif chemokine 11 measurement
EFO:0005035	hippocampal volume

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C566443	Complement Component 7 Deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712964 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs56061981	Efficacy	3	peginterferon alfa-2a;peginterferon alfa-2b	Chronic hepatitis C virus infection

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs56061981	ART3, CXCL10	3	2.75	1	peginterferon alfa-2a;peginterferon alfa-2b

Binding affinities (BindingDB)

203 measured of 203 human assays (203 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(3S)-3-(4-chlorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl-propylamino]propanoic acid	IC50	11 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	12 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chloro-3-fluorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	19 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	20 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl-propylamino]propanoic acid	IC50	20 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]-3-methoxyphenyl]methyl]amino]-3-(3,4-dichlorophenyl)propanoic acid	IC50	20 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chlorophenyl)-3-[[3-methoxy-4-[2-(3-methyl-2,6-dioxo-1,3-diazinan-1-yl)ethoxy]phenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	23 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[butyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]-3-(4-chloro-3-fluorophenyl)propanoic acid	IC50	23 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl-propylamino]propanoic acid	IC50	25 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclohexylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	28 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopropylmethyl-[[3-methoxy-4-[2-(3-methyl-2,6-dioxo-1,3-diazinan-1-yl)ethoxy]phenyl]methyl]amino]-3-(3,4-dichlorophenyl)propanoic acid	IC50	30 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3R)-3-(4-chlorophenyl)-3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl]amino]propanoic acid	IC50	31 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[butyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl]amino]-3-(4-chlorophenyl)propanoic acid	IC50	31 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	31 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chloro-3-fluorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	32 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	34 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]propanoic acid	IC50	34 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopentylmethyl-[[3-methoxy-4-[2-(3-methyl-2,6-dioxo-1,3-diazinan-1-yl)ethoxy]phenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	38 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]-3-(3,4-dichlorophenyl)propanoic acid	IC50	39 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-[[3-chloro-4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]phenyl]methyl-(cyclopropylmethyl)amino]-3-(4-chloro-3-fluorophenyl)propanoic acid	IC50	40 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[cyclohexylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	40 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	40 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(2,3-dihydro-1-benzofuran-5-yl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	41 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chlorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]propanoic acid	IC50	42 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopropylmethyl-[[3-methyl-4-[2-(3-methyl-2,6-dioxo-1,3-diazinan-1-yl)ethoxy]phenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	42 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[cyclohexylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	43 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(2,3-dihydro-1-benzofuran-5-yl)-3-[[4-[3-(2,5-dioxopyrrolidin-1-yl)propyl]-3-methoxyphenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	43 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl]amino]propanoic acid	IC50	45 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	46 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl]amino]propanoic acid	IC50	50 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[cyclohexylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl]amino]propanoic acid	IC50	51 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[butyl-[[4-[3-(2,5-dioxopyrrolidin-1-yl)propyl]-3-methoxyphenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	51 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-fluorophenyl]methyl]amino]propanoic acid	IC50	52 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chloro-3-fluorophenyl)-3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	54 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chlorophenyl)-3-[cyclobutylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]propanoic acid	IC50	54 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[butyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]-3-(4-chloro-3-fluorophenyl)propanoic acid	IC50	54 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopentylmethyl-[[4-[3-(2,5-dioxopyrrolidin-1-yl)propyl]-3-methoxyphenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	54 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chlorophenyl)-3-[cyclohexylmethyl-[[3-methyl-4-[2-(3-methyl-2,5-dioxoimidazolidin-1-yl)ethoxy]phenyl]methyl]amino]propanoic acid	IC50	55 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(3,4-dichlorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]-3-methoxyphenyl]methyl-propylamino]propanoic acid	IC50	55 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl-propylamino]propanoic acid	IC50	56 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid	IC50	56 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3S)-3-(4-chloro-3-fluorophenyl)-3-[cyclopropylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-fluorophenyl]methyl]amino]propanoic acid	IC50	58 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chlorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-ethylphenyl]methyl-propylamino]propanoic acid	IC50	58 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(2,3-dihydro-1-benzofuran-5-yl)-3-[ethyl-[[3-methyl-4-[2-(3-methyl-2,6-dioxo-1,3-diazinan-1-yl)ethoxy]phenyl]methyl]amino]propanoic acid	IC50	58 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
(3R)-3-(4-chloro-3-fluorophenyl)-3-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl-(2-methylpropyl)amino]propanoic acid	IC50	59 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[butyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]-3-(3,4-dichlorophenyl)propanoic acid	IC50	61 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methoxyphenyl]methyl]amino]-3-(3,4-dichlorophenyl)propanoic acid	IC50	61 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-[butyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]-3-(4-chlorophenyl)propanoic acid	IC50	61 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-3-methylphenyl]methyl]amino]propanoic acid	IC50	61 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists
3-(4-chloro-3-fluorophenyl)-3-[cyclopentylmethyl-[[4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]-3-methoxyphenyl]methyl]amino]propanoic acid	IC50	62 nM	US-9447038: Substituted B-amino acid derivatives as CXCR3 receptor antagonists

CTD chemical–gene interactions

206 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Lipopolysaccharides	decreases reaction, increases expression, increases secretion, increases reaction, affects cotreatment (+1 more)	14
Poly I-C	affects cotreatment, decreases reaction, increases expression, increases secretion	7
Particulate Matter	increases expression, decreases expression, decreases reaction, increases abundance, affects expression (+1 more)	6
Vehicle Emissions	decreases expression, decreases reaction, increases reaction, increases secretion, affects expression (+2 more)	5
perfluorooctanoic acid	decreases expression	4
lipopolysaccharide, E. coli O26-B6	increases expression, decreases reaction, affects reaction	4
tofacitinib	decreases expression, decreases secretion, decreases reaction, increases expression	4
Benzo(a)pyrene	increases expression, increases methylation, decreases reaction	4
Estradiol	affects cotreatment, decreases expression, increases expression, decreases reaction	4
Quercetin	decreases expression, decreases reaction, increases expression, affects cotreatment, increases secretion (+2 more)	4
Silicon Dioxide	increases expression	4
3,4,5,3’,4’-pentachlorobiphenyl	increases expression, decreases expression	3
nickel sulfate	affects cotreatment, increases expression, decreases reaction, increases secretion	3
perfluorooctane sulfonic acid	decreases expression	3
Resveratrol	decreases expression, decreases secretion, decreases reaction, increases expression, increases secretion (+1 more)	3
Cannabidiol	decreases reaction, increases expression, increases secretion, affects cotreatment	3
Smoke	decreases reaction, increases expression, increases secretion, decreases expression, increases abundance	3
Tetrachlorodibenzodioxin	decreases expression, increases expression, affects expression	3
Tobacco Smoke Pollution	decreases secretion, decreases expression	3
bisphenol A	affects cotreatment, increases expression, decreases secretion	2
sodium arsenite	decreases expression, increases expression	2
nickel chloride	decreases reaction, increases expression	2
1-nitropyrene	increases expression	2
acetovanillone	decreases reaction, increases expression	2
polydatin	decreases reaction, increases secretion, decreases expression, decreases secretion, affects cotreatment (+1 more)	2
acteoside	affects cotreatment, decreases secretion, increases reaction, decreases expression, decreases reaction (+1 more)	2
vanadium pentoxide	decreases reaction, increases expression	2
macrophage stimulatory lipopeptide 2	decreases reaction, affects cotreatment, increases expression, increases secretion	2
monomethylarsonous acid	affects expression, decreases expression	2
FSL-1 lipoprotein, synthetic	increases secretion, affects cotreatment, increases expression, decreases reaction	2

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5046331	Binding	Binding affinity to human CXCL10 at 100 uM by glycan microarray analysis	Heparan Sulfate Mimetics Differentially Affect Homologous Chemokines and Attenuate Cancer Development. — J Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8CC	THP1-Blue KI-IP10	Cancer cell line	Male
CVCL_B1AC	Abcam THP-1 CXCL10 KO	Cancer cell line	Male
CVCL_B1EY	Abcam A-549 CXCL10 KO 2	Cancer cell line	Male
CVCL_B2MG	Abcam A-549 CXCL10 KO 1	Cancer cell line	Male
CVCL_B2MH	Abcam A-549 CXCL10 KO 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.